Russell JP, Lim X, Santambrogio A, Yianni V, Kemkem Y, Wang B, Fish M, Haston S, Grabek A, Hallang S, Lodge EJ, Patist AL, Schedl A, Mollard P, Nusse R, Andoniadou CL (2021) Pituitary stem cells produce paracrine WNT signals to control the expansion of their descendant progenitor cells. Elife 10. https://doi.org/10.7554/eLife.59142
Laporte E, Vennekens A, Vankelecom H (2020) Pituitary remodeling throughout life: are Resident Stem cells involved? Front Endocrinol (Lausanne) 11:604519. https://doi.org/10.3389/fendo.2020.604519
Nys C, Lee YL, Roose H, Mertens F, De Pauw E, Kobayashi H, Sciot R, Bex M, Versyck G, De Vleeschouwer S, Van Loon J, Laporte E, Vankelecom H (2022) Exploring stem cell biology in pituitary tumors and derived organoids. Endocr Relat Cancer 29(7):427–450. https://doi.org/10.1530/ERC-21-0374
Article CAS PubMed Google Scholar
Alexander JM, Biller BM, Bikkal H, Zervas NT, Arnold A, Klibanski A (1990) Clinically nonfunctioning pituitary tumors are monoclonal in origin. J Clin Invest 86(1):336–340. https://doi.org/10.1172/JCI114705
Article CAS PubMed PubMed Central Google Scholar
Herman V, Fagin J, Gonsky R, Kovacs K, Melmed S (1990) Clonal origin of pituitary adenomas. J Clin Endocrinol Metab 71(6):1427–1433. https://doi.org/10.1210/jcem-71-6-1427
Article CAS PubMed Google Scholar
Clayton RN, Farrell WE (2001) Clonality of pituitary tumours: more complicated than initially envisaged? Brain Pathol 11(3):313–327. https://doi.org/10.1111/j.1750-3639.2001.tb00402.x
Article CAS PubMed Google Scholar
Clayton RN, Pfeifer M, Atkinson AB, Belchetz P, Wass JA, Kyrodimou E, Vanderpump M, Simpson D, Bicknell J, Farrell WE (2000) Different patterns of allelic loss (loss of heterozygosity) in recurrent human pituitary tumors provide evidence for multiclonal origins. Clin Cancer Res 6(10):3973–3982
Cheung LY, Rizzoti K (2020) Cell population characterisation and discovery using single cell technologies in endocrine systems. J Mol Endocrinol. https://doi.org/10.1530/JME-19-0276
Haston S, Manshaei S, Martinez-Barbera JP (2018) Stem/progenitor cells in pituitary organ homeostasis and tumourigenesis. J Endocrinol 236(1):R1–R13. https://doi.org/10.1530/JOE-17-0258
Article CAS PubMed Google Scholar
Wurth R, Barbieri F, Pattarozzi A, Gaudenzi G, Gatto F, Fiaschi P, Ravetti JL, Zona G, Daga A, Persani L, Ferone D, Vitale G, Florio T (2017) Phenotypical and pharmacological characterization of Stem-Like cells in human pituitary adenomas. Mol Neurobiol 54(7):4879–4895. https://doi.org/10.1007/s12035-016-0025-x
Article CAS PubMed Google Scholar
Chen L, Ye H, Wang X, Tang X, Mao Y, Zhao Y, Wu Z, Mao XO, Xie L, Jin K, Yao Y (2014) Evidence of brain tumor stem progenitor-like cells with low proliferative capacity in human benign pituitary adenoma. Cancer Lett 349(1):61–66. https://doi.org/10.1016/j.canlet.2014.03.031
Article CAS PubMed Google Scholar
Xu Q, Yuan X, Tunici P, Liu G, Fan X, Xu M, Hu J, Hwang JY, Farkas DL, Black KL, Yu JS (2009) Isolation of tumour stem-like cells from benign tumours. Br J Cancer 101(2):303–311. https://doi.org/10.1038/sj.bjc.6605142
Article CAS PubMed PubMed Central Google Scholar
Mertens F, Gremeaux L, Chen J, Fu Q, Willems C, Roose H, Govaere O, Roskams T, Cristina C, Becú-Villalobos D, Jorissen M, Poorten VV, Bex M, Loon Jv, Vankelecom H (2015) Pituitary tumors contain a side population with tumor stem cell-associated characteristics. 22(4):481. https://doi.org/10.1530/erc-14-0546
Manoranjan B, Mahendram S, Almenawer SA, Venugopal C, McFarlane N, Hallett R, Vijayakumar T, Algird A, Murty NK, Sommer DD, Provias JP, Reddy K, Singh SK (2016) The identification of human pituitary adenoma-initiating cells. Acta Neuropathol Commun 4(1):125. https://doi.org/10.1186/s40478-016-0394-4
Article CAS PubMed PubMed Central Google Scholar
Peverelli E, Giardino E, Treppiedi D, Meregalli M, Belicchi M, Vaira V, Corbetta S, Verdelli C, Verrua E, Serban AL, Locatelli M, Carrabba G, Gaudenzi G, Malchiodi E, Cassinelli L, Lania AG, Ferrero S, Bosari S, Vitale G, Torrente Y, Spada A, Mantovani G (2017) Dopamine receptor type 2 (DRD2) and somatostatin receptor type 2 (SSTR2) agonists are effective in inhibiting proliferation of progenitor/stem-like cells isolated from nonfunctioning pituitary tumors. Int J Cancer 140(8):1870–1880. https://doi.org/10.1002/ijc.30613
Article CAS PubMed Google Scholar
Perez Millan MI, Cheung LYM, Mercogliano F, Camilletti MA, Chirino Felker GT, Moro LN, Miriuka S, Brinkmeier ML, Camper SA (2023) Pituitary stem cells: past, present and future perspectives. Nat Rev Endocrinol. https://doi.org/10.1038/s41574-023-00922-4
Zhang Z, Zamojski M, Smith GR, Willis TL, Yianni V, Mendelev N, Pincas H, Seenarine N, Amper MAS, Vasoya M, Cheng WS, Zaslavsky E, Nair VD, Turgeon JL, Bernard DJ, Troyanskaya OG, Andoniadou CL, Sealfon SC, Ruf-Zamojski F (2022) Single nucleus transcriptome and chromatin accessibility of postmortem human pituitaries reveal diverse stem cell regulatory mechanisms. Cell Rep 38(10):110467. https://doi.org/10.1016/j.celrep.2022.110467
Article CAS PubMed PubMed Central Google Scholar
Lloyd RV, Kloppel OR, Rosai G (2017) J: WHO classification of tumours of endocrine organs, vol 10, 4 edn. IARC, Lyon
Lenders NF, Wilkinson AC, Wong SJ, Shein TT, Harvey RJ, Inder WJ, Earls PE, McCormack AI (2021) Transcription factor immunohistochemistry in the diagnosis of pituitary tumours. Eur J Endocrinol. https://doi.org/10.1530/EJE-20-1273
Tordjman KM, Greenman Y, Ram Z, Hershkovitz D, Aizenstein O, Ariel O, Asa SL (2019) Plurihormonal Pituitary Tumor of Pit-1 and SF-1 lineages, with Synchronous Collision Corticotroph Tumor: a possible stem cell phenomenon. Endocr Pathol 30(1):74–80. https://doi.org/10.1007/s12022-018-9562-3
Article CAS PubMed Google Scholar
Mete O, Alshaikh OM, Cintosun A, Ezzat S, Asa SL (2018) Synchronous multiple pituitary neuroendocrine tumors of different cell lineages. Endocr Pathol 29(4):332–338. https://doi.org/10.1007/s12022-018-9545-4
Article CAS PubMed Google Scholar
Asa SL, Mete O, Perry A, Osamura RY (2022) Overview of the 2022 WHO classification of Pituitary tumors. Endocr Pathol 33(1):6–26. https://doi.org/10.1007/s12022-022-09703-7
Article CAS PubMed Google Scholar
Tahara S, Kurotani R, Ishii Y, Sanno N, Teramoto A, Osamura RY (2002) A case of Cushing’s disease caused by pituitary adenoma producing adrenocorticotropic hormone and growth hormone concomitantly: aberrant expression of transcription factors NeuroD1 and Pit-1 as a proposed mechanism. Mod Pathol 15(10):1102–1105. https://doi.org/10.1097/01.MP.0000030451.28828.00
Torregrosa-Quesada ME, Garcia-Martinez A, Silva-Ortega S, Martinez-Lopez S, Camara R, Fajardo C, Lamas C, Aranda I, Pico A (2019) How Valuable is the RT-qPCR of Pituitary-Specific Transcription Factors for identifying Pituitary neuroendocrine tumor subtypes according to the New WHO 2017 Criteria? Cancers (Basel) 11(12). https://doi.org/10.3390/cancers11121990
Lenders NF, Chui J, Low J, Inder WJ, Earls PE, McCormack AI (2022) Development of a cost-effective diagnostic algorithm incorporating transcription factor immunohistochemistry in the evaluation of pituitary tumours. Pituitary 25(6):997–1003. https://doi.org/10.1007/s11102-022-01284-2
Article CAS PubMed PubMed Central Google Scholar
Horvath E, Kovacs K, Smyth HS, Cusimano M, Singer W (2005) Silent adenoma subtype 3 of the pituitary–immunohistochemical and ultrastructural classification: a review of 29 cases. Ultrastruct Pathol 29(6):511–524. https://doi.org/10.1080/01913120500323514
Article CAS PubMed Google Scholar
Erickson D, Scheithauer B, Atkinson J, Horvath E, Kovacs K, Lloyd RV, Young WF Jr. (2009) Silent subtype 3 pituitary adenoma: a clinicopathologic analysis of the Mayo Clinic experience. Clin Endocrinol (Oxf) 71(1):92–99. https://doi.org/10.1111/j.1365-2265.2008.03514.x
Article CAS PubMed Google Scholar
Mete O, Gomez-Hernandez K, Kucharczyk W, Ridout R, Zadeh G, Gentili F, Ezzat S, Asa SL (2016) Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas. Mod Pathol 29(2):131–142. https://doi.org/10.1038/modpathol.2015.151
Article CAS PubMed Google Scholar
Richardson TE, Shen ZJ, Kanchwala M, Xing C, Filatenkov A, Shang P, Barnett S, Abedin Z, Malter JS, Raisanen JM, Burns DK, White CL, Hatanpaa KJ (2017) Aggressive behavior in Silent Subtype III Pituitary Adenomas May depend on suppression of local Immune response: a whole transcriptome analysis. J Neuropathol Exp Neurol 76(10):874–882. https://doi.org/10.1093/jnen/nlx072
Article CAS PubMed Google Scholar
Fountas A, Lavrentaki A, Subramanian A, Toulis KA, Nirantharakumar K, Karavitaki N (2018) Recurrence in silent corticotroph adenomas after primary treatment: a systematic review and meta-analysis. J Clin Endocrinol Metab. https://doi.org/10.1210/jc.2018-01956
Richardson TE, Mathis DA, Mickey BE, Raisanen JM, Burns DK, White CL 3rd, Hatanpaa KJ (2015) Clinical outcome of Silent Subtype III Pituitary Adenomas diagnosed by immunohistochemistry. J Neuropathol Exp Neurol 74(12):1170–1177. https://doi.org/10.1097/NEN.0000000000000265
Article CAS PubMed Google Scholar
Pereira BD, Raimundo L, Mete O, Oliveira A, Portugal J, Asa SL (2016) Monomorphous Plurihormonal Pituitary Adenoma of Pit-1 lineage in a giant adolescent with central hyperthyroidism. Endocr Pathol 27(1):25–33. https://doi.org/10.1007/s12022-015-9395-2
Mete O, Lopes MB (2017) Overview of the 2017 WHO classification of Pituitary tumors. Endocr Pathol 28(3):228–243. https://doi.org/10.1007/s12022-017-9498-z
Article CAS PubMed Google Scholar
Delfin L, Mete O, Asa SL (2021) Follicular cells in pituitary neuroendocrine tumors. Hum Pathol 114:1–8. https://doi.org/10.1016/j.humpath.2021.05.002
Comments (0)